Table 1
General demographics and histology.
| General Demographics | n | Histology | n |
|---|---|---|---|
| Patients | 100 | SCC | 14 |
| Median age (range) | 59.3 (26-79) | AC | 73 |
| Males/Females | 80/20 | NSCLC-NOS | 13 |
[i] SCC: squamous cell carcinoma; AC: adenocarcinoma;
NSCLC-NOS: non-small cell lung cancer-not otherwise specified.
Table 2
Targetable mutations in squamous cell carcinoma patients.
| n | Activating Mutation(s) | Resistance Mutation |
|---|---|---|
| 24 | MET exon 14 I491T | |
| 29 | MET exon 14 V1014V | |
| 56 | EGFR exon 21 L858R | EGFR exon 20 T790M |
Table 3
Detailed Molecular Findings of Adenocarcinoma and NSLC-NOS patients with detectable EGFR mutations
| Patient Number | Activating Mutation(s) | Resistance Mutation(s) | Polymorphism |
|---|---|---|---|
| 2 | EGFR Exon 19 A750P, EGFR Exon 19 L747_E749 del | ||
| 4 | EGFR Exon 19 | ||
| 6 | EGFR Exon 21 L858R | EGFR Exon 20 T790M | |
| 7 | EGFR Exon 20 C797S EGFR Exon 21 L858R | EGFR Exon 20 T790M | |
| 10 | EGFR Exon 18 G721V | ||
| 12 | EGFR Exon 20 S768I EGFR Exon 21 L858R | ||
| 15 | EGFR Exon 21 L858R | ||
| 33 | KRAS Exon 2 G12C | EGFR Exon 13 R521K | |
| 38 | EGFR Exon 19 E746_A750del | ||
| 39 | EGFR Exon 18 G721S | ||
| 40 | EGFR Exon 20 S784T | ||
| 41 | EGFR Exon 19 P753P | ||
| 48 | EGFR Exon 19 T751_E758del | ||
| 50 | EGFR Exon 19 L747_P753delinsS | ||
| 53 | EGFR Exon 20 A767_V469 duplication ERBB2 amplification | ||
| 55 | EGFR Exon 19 E746_A750del | ||
| 57 | EGFR Exon 19 E746_T751delinsA | ||
| 63 | EGFR Exon 20 T790M EGFR Exon 20 C797S | ||
| 69 | EGFR Exon 18 I706S | ||
| 73 | EGFR Exon 20 H773fs *53, Met amplification | ||
| 78 | EGFR Exon 20 K806I, Met Exon 14 R988H, Met Exon 14 Y989C | ||
| 80 | KRAS Exon 2 G12C | EGFR Exon 13 R521K | |
| 81 | EGFR Exon 20 D807fs *90 | ||
| 84 | EGFR Exon 20 V786L | ||
| 85 | EGFR Exon 21 A864T | ||
| 86 | EGFR Exon 19 L747_T751del | KRAS Exon 2 G12S, Met Exon 14 E1012K | |
| 88 | EGFR Exon 19 E746_A750delELRE A, EGFR Amplification |
Table 4
Detailed molecular findings of adenocarcinoma and non-small cell lung cancer-not otherwise specified patients other than EGFR mutations.
| # | Activating Mutation(s) | Resistance Mutation(s) | Polymorphism |
|---|---|---|---|
| 5 | KRAS exon 2 G12C | ||
| 33 | KRAS exon 2 G12C | EGFR exon 13 R521K | |
| 37 | KRAS exon 2 G12V | ||
| 49 | KRAS exon 2 G12V (c.35G>T) | ||
| 80 | KRAS exon 2 G12C | EGFR exon 13 R521K | |
| 86 | EGFR exon 19 L747_T751del; MET exon 14 E1012K | KRAS exon 2 G12S | |
| 87 | KRAS exon 2 G12D | ||
| 90 | KRAS intron 2 | ||
| 14 | MET amplification | ||
| 73 | EGFR exon 20 H773fs*53; MET amplification | ||
| 78 | EGFR exon 20 K806I; MET exon 14 R988H; MET exon 14 Y989C | ||
| 44 | ALK exon 29 K1491R | ERBB2 exon 17 I655V | EGFR exon 13 R521K |
| 95 | ALK exon 22 C1156S | ||
| 31 | ERBB2 amplification | ||
| 53 | EGFR exon 20 A767_V469dup; ERBB2 amplification | ||
| 79 | ERBB2 exon 17 I655V | ||
| 58 | PDGFRA c.236G>A (G79D); KIT c.2362-77G>A | ||
| 18 | BRAF exon 11 G469E |
Table 5
Second liquid biopsy results in adenocarcinoma and non-small cell lung cancer-not otherwise specified patients.
| # | First Liquid Biopsy | Second Liquid Biopsy | Prior Treatment |
|---|---|---|---|
| 2 | EGFR exon 19 A750P; EGFR exon 19 L747_E749del | no variant detected | erlotinib |
| 10 | EGFR exon 18 G721V | no variant detected | paclitaxel + carboplatin |
| 13 | no variant detected | no variant detected | paclitaxel + carboplatin |
| 15 | EGFR exon 21 L858R | BRAF exon 15 R603* | erlotinib |
| 31 | ERBB2 amplification | no variant detected | paclitaxel + carboplatin |
| 38 | EGFR exon 19 E746_A750del | no variant detected | erlotinib |
| 55 | EGFR exon 19 E746_A750del | EGFR exon 19 E746_A750del; EGFR exon 20 T790M | erlotinib |
| 95 | ALK exon 22 C1156S | no variant detected | crizotinib |